Teva to lose grip on Copaxone next year
20-11-2013
On January 28, Teva announced that the US Food and Drug Administration (FDA) had approved its supplemental new drug application for a new formulation of its biggest selling drug Copaxone.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Copaxone, Teva, FDA, dosage, dosage patent
